MEDI7352 / AstraZeneca - LARVOL DELTA

Efficacy and Safety of MEDI7352 in Participants With Painful Diabetic Neuropathy (clinicaltrials.gov) - P2 | N=112 | Terminated | Sponsor: AstraZeneca | Completed ➔ Terminated; The study was prematurely terminated due to longer enrolment time than was anticipated.

Trial termination • Diabetic Neuropathy • Pain

MEDI7352: Data from P2 trial (NCT03755934) for painful diabetic neuropathy in H2 2023 (AstraZeneca) - Q3 2023 Results

P2 data • Diabetic Nephropathy • Pain

Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy (clinicaltrials.gov) - P2 | N=112 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed | Trial completion date: Jun 2024 ➔ Jun 2023 | Trial primary completion date: Jun 2024 ➔ Jun 2023

Trial completion • Trial completion date • Trial primary completion date • Diabetic Neuropathy • Pain

BESPOKE: A Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee (clinicaltrials.gov) - P2 | N=390 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion • Immunology • Osteoarthritis • Pain • Rheumatology

MEDI7352: Data from P2 BESPOKE trial (NCT04675034) for painful osteoarthritis of the knee in H2 2023 (AstraZeneca) - H1 and Q2 2023 Results: Data from P2 trial (NCT03755934) for painful diabetic neuropathy in H2 2024

P2 data • Pain

Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy (clinicaltrials.gov) - P2 | N=112 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetic Neuropathy • Pain

MEDI7352: Data from P2 trial (NCT03755934) for painful diabetic neuropathy in 2024 (AstraZeneca) - Q4 & FY2022 Results: Data from P2 BESPOKE trial (NCT04675034) for painful osteoarthritis of the knee in H2 2023

P2 data • Pain

Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy (clinicaltrials.gov) - P2 | N=111 | Recruiting | Sponsor: AstraZeneca | N=81 ➔ 111

Enrollment change • Diabetic Neuropathy • Pain

BESPOKE: A Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee (clinicaltrials.gov) - P2 | N=317 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Osteoarthritis • Pain • Rheumatology

MEDI7352: Data from P2 trial (NCT03755934) for painful diabetic neuropathy post 2023 (AstraZeneca) - H1 2022 Results: Data from P2 BESPOKE trial (NCT04675034) for painful osteoarthritis of the knee in H2 2023

P2 data • Pain

Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy (clinicaltrials.gov) - P2 | N=111 | Recruiting | Sponsor: AstraZeneca | N=271 ➔ 111

Enrollment change • Diabetic Neuropathy • Pain

Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy (clinicaltrials.gov) - P2 | N=271 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Aug 2023 ➔ Jun 2024 | Trial primary completion date: Aug 2023 ➔ Jun 2024

Trial completion date • Trial primary completion date • Diabetic Neuropathy • Pain

MEDI7352: Data from P2 trial (NCT03755934) for painful diabetic neuropathy in 2023 (AstraZeneca) - FY 2021 Results: Data from P2 BESPOKE trial (NCT04675034) for painful osteoarthritis of the knee in 2023

P2 data • Pain

Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy (clinicaltrials.gov) - P2; N=271; Recruiting; Sponsor: AstraZeneca; Trial completion date: May 2023 ➔ Aug 2023; Trial primary completion date: May 2023 ➔ Aug 2023

Clinical • Trial completion date • Trial primary completion date • Diabetic Neuropathy • Pain

Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI7352 in Healthy Volunteers (clinicaltrials.gov) - P1; N=24; Completed; Sponsor: AstraZeneca; Active, not recruiting ➔ Completed

Clinical • Trial completion • Immunology • Osteoarthritis • Pain • Rheumatology

MEDI7352: Data from P1 trial (NCT04770428) for healthy volunteers in Q4 2021 (AstraZeneca) - Q3 2021 Results

P1 data • Pain

Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI7352 in Healthy Volunteers (clinicaltrials.gov) - P1; N=23; Active, not recruiting; Sponsor: AstraZeneca; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Immunology • Osteoarthritis • Pain • Rheumatology

MEDI7352: Data from P2 BESPOKE trial (NCT04675034) for painful osteoarthritis of the knee in H2 2022 (AstraZeneca) - H1 2021 Results: Data from P2 trial (NCT03755934) for painful diabetic neuropathy in H2 2022

P2 data • Pain

Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy (clinicaltrials.gov) - P2; N=271; Recruiting; Sponsor: AstraZeneca; Trial completion date: Feb 2022 ➔ May 2023; Trial primary completion date: Feb 2022 ➔ May 2023

Clinical • Trial completion date • Trial primary completion date • Diabetic Neuropathy • Pain

[VIRTUAL] Phase1 Data With a NGF/TNF? Bispecific in Patients With Painful Osteoarthritis of the Knee (IASP 2021) - "MEDI7352 is well tolerated and produces significant decreases in pain endpoints in subjects with painful osteoarthritis of the knee"

Clinical • P1 data • Addiction (Opioid and Alcohol) • Immunology • Osteoarthritis • Pain • Rheumatology

BESPOKE: A Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee (clinicaltrials.gov) - P2; N=300; Recruiting; Sponsor: AstraZeneca; Trial completion date: Aug 2022 ➔ Dec 2022; Trial primary completion date: Aug 2022 ➔ Dec 2022

Clinical • Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

MEDI7352: Data from P1 trial (NCT02508155) for painful osteoarthritis in Q2 2021 (AstraZeneca) - Q1 2021 Results: Data from P2 trial (NCT03755934) for painful diabetic neuropathy in H2 2021

P1 data • P2 data • Pain

MEDI7352: Data from P2 BESPOKE trial (NCT04675034) for painful osteoarthritis of the knee in H1 2022 (AstraZeneca) - Q1 2021 Results: Data from P1 trial (NCT04770428) for healthy volunteers in H2 2021

P1 data • P2 data • Pain

Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI7352 in Healthy Volunteers (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: AstraZeneca; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Immunology • Osteoarthritis • Pain • Rheumatology

Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy (clinicaltrials.gov) - P2; N=271; Recruiting; Sponsor: AstraZeneca; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open • Diabetic Neuropathy • Pain